Regulators in Ontario are pursuing millions of dollars in penalties against a prominent businessman from the London area, alleging he orchestrated a multimillion-dollar securities fraud by selling shares in a British Columbia-based biotechnology firm.
The Ontario Securities Commission (OSC) has concluded its investigation into Robert Freeman, a 72-year-old entrepreneur based in Thorndale. According to regulatory filings, the OSC alleges that Freeman “perpetuated a fraud” and deceived investors while offloading shares of Qu Biologics Inc. (QBI), a company he helped establish.
At the center of the dispute is the sale of securities totaling $4.8 million. The OSC alleges that between 2009 and 2024, Freeman sold these shares to 190 different investors. Rather than following standard regulatory protocols, the commission claims Freeman transferred the resulting funds into accounts belonging to his own company, Plover Mills Farms Inc.
Freeman, who gained significant regional prominence after selling his company, London Telecom, for $76 million in 1999, has denied the allegations of fraud. He maintains that the situation is a misunderstanding of complex regulations and has retained legal counsel to contest the proceedings.
The Mechanics of the Alleged Fraud
The OSC’s case hinges on the claim that Freeman created a deceptive legal structure to bypass board approval and registration requirements. The filing alleges that Freeman used investor agreements to give buyers the false impression that share titles could be transferred to them while simultaneously being held by Freeman in trust.
Under the company’s governing rules, the OSC asserts that Freeman could not legally sell his shares without the explicit approval of the Qu Biologics board of directors. The regulator alleges that Freeman occasionally misrepresented himself to investors, claiming he was acting on behalf of other shareholders who wished to sell.
From a regulatory standpoint, the OSC highlights a critical failure in the “qualification” of the buyers. Because no prospectus—a detailed financial disclosure document required for public offerings—was issued, the sales were only legal if the investors met specific “accredited investor” exemptions. The OSC contends these purchasers were not properly qualified.
“Freeman has never been registered to engage in the business of trading and his sales of QBI shares breached the registration agreement,” the OSC document states, adding that the conduct constituted “illegal distributions and unregistered trading.”
A History of Entrepreneurship and Adversity
To understand Robert Freeman’s trajectory, one must look back to 1988, when he founded London Telecom. In an era before the internet democratized communication, Freeman built a network of long-distance lines that challenged the dominance of giants like Bell. That venture culminated in a $76 million sale to Primus in 1999, providing the capital for his estate, Avalon, on the shores of the Thames River.
However, the wealth of the telecom sale was followed by a severe health crisis. Freeman was diagnosed with non-Hodgkin’s lymphoma, a cancer of the lymphatic system. He describes a harrowing period where he believed he had only a five percent chance of survival, leading him to travel globally in search of alternative treatments.
This search led him to Vancouver and Dr. Hal Gunn, whose immunotherapy methods Freeman credits with saving his life. This relationship transitioned from patient-doctor to business partners. Freeman became an investor and director in Qu Biologics, the firm now at the center of the OSC investigation.
Qu Biologics is not a publicly traded company. Its research focuses on restoring innate immune function in specific organs, with several patents pending and clinical trials underway.
The Defense: ‘Naivety’ vs. Intent
Freeman’s defense rests on the assertion that there was never any intent to defraud. He describes his actions as an attempt to assist others gain access to a company they otherwise would not have qualified to invest in.
According to Freeman, he utilized a $2-million personal bank loan to acquire shares and then sold them to interested parties via trust agreements. He argues that he did not actively solicit these buyers, but rather that investors approached him. Regarding the flow of funds into Plover Mills Farms, Freeman explains that the money was used to repay the original bank loan used for the share purchases.
“There’s no fraud, there’s no ill intention here,” Freeman stated, adding that he was unaware that the QBI board needed to be notified of sales conducted under a trust agreement. He characterized himself as “a little bit naive” regarding the intricacies of securities law, suggesting he is being “hung out to dry” for a regulatory oversight rather than a criminal act.
Beyond biotech, Freeman has pursued unconventional ventures, including “Vision Without Eyes,” a company offering seminars on “mind sight” for the visually impaired, and a “passion project” arranging UFO research expeditions to Peru.
Legal Stakes and Next Steps
The OSC has categorized this as a regulatory case rather than a quasi-criminal one, though the financial implications remain severe. The regulator has already obtained orders barring Freeman from trading securities while the case proceeds.
The potential penalties are significant. The OSC has requested that the tribunal be permitted to apply fines, penalties, and court costs of up to $5 million for each individual failure to comply with the Ontario Securities Act. The tribunal has the power to order the repayment of investors and permanently ban Freeman from serving as a company director.
| Year | Event |
|---|---|
| 1988 | Freeman founds London Telecom |
| 1999 | London Telecom sold for $76 million |
| 2009–2024 | Period of alleged illegal share sales of Qu Biologics |
| Feb 9 | Preliminary hearing held by Capital Markets Commission |
| June | Scheduled case management conference |
Qu Biologics has distanced itself from the controversy. In a statement, CEO Hal Gunn noted that while Freeman was an original investor, he has had “no active role” in the company for 12 years. The company emphasized that its board would never support the sale of shares to non-accredited investors.
Disclaimer: This article is for informational purposes only and does not constitute legal or financial advice.
The next confirmed checkpoint in this matter is a case management conference scheduled for June, which will serve as a preliminary stage of the hearing process to determine how the case will proceed toward a final decision.
We invite readers to share their perspectives on the balance between regulatory strictness and entrepreneurial “naivety” in the comments below.
